These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

739 related articles for article (PubMed ID: 19581539)

  • 41. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
    de Vos S; Goy A; Dakhil SR; Saleh MN; McLaughlin P; Belt R; Flowers CR; Knapp M; Hart L; Patel-Donnelly D; Glenn M; Gregory SA; Holladay C; Zhang T; Boral AL
    J Clin Oncol; 2009 Oct; 27(30):5023-30. PubMed ID: 19770386
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.
    Ansell SM; Inwards DJ; Rowland KM; Flynn PJ; Morton RF; Moore DF; Kaufmann SH; Ghobrial I; Kurtin PJ; Maurer M; Allmer C; Witzig TE
    Cancer; 2008 Aug; 113(3):508-14. PubMed ID: 18543327
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Robertson MJ; Kahl BS; Vose JM; de Vos S; Laughlin M; Flynn PJ; Rowland K; Cruz JC; Goldberg SL; Musib L; Darstein C; Enas N; Kutok JL; Aster JC; Neuberg D; Savage KJ; LaCasce A; Thornton D; Slapak CA; Shipp MA
    J Clin Oncol; 2007 May; 25(13):1741-6. PubMed ID: 17389337
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
    Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
    Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations.
    Boni JP; Hug B; Leister C; Sonnichsen D
    Semin Oncol; 2009 Dec; 36 Suppl 3():S18-25. PubMed ID: 19963096
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
    Hudes GR; Berkenblit A; Feingold J; Atkins MB; Rini BI; Dutcher J
    Semin Oncol; 2009 Dec; 36 Suppl 3():S26-36. PubMed ID: 19963097
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series.
    Lunardi G; Armirotti A; Nicodemo M; Cavallini L; Damonte G; Vannozzi MO; Venturini M
    Clin Ther; 2009 Aug; 31(8):1812-9. PubMed ID: 19808140
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT).
    Rosenbluth BD; Yahalom J
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1185-91. PubMed ID: 16682133
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Concurrent involved field radiation therapy and temsirolimus in refractory mantle cell lymphoma (MCL).
    Kirova YM; Chargari C; Amessis M; Vernant JP; Dhedin N
    Am J Hematol; 2010 Nov; 85(11):892. PubMed ID: 20721889
    [No Abstract]   [Full Text] [Related]  

  • 50. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
    Amato RJ; Jac J; Giessinger S; Saxena S; Willis JP
    Cancer; 2009 Jun; 115(11):2438-46. PubMed ID: 19306412
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Temsirolimus in renal cell carcinoma.
    Otto T; Eimer C; Gerullis H
    Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
    Friedberg JW; Cohen P; Chen L; Robinson KS; Forero-Torres A; La Casce AS; Fayad LE; Bessudo A; Camacho ES; Williams ME; van der Jagt RH; Oliver JW; Cheson BD
    J Clin Oncol; 2008 Jan; 26(2):204-10. PubMed ID: 18182663
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.
    Renner C; Zinzani PL; Gressin R; Klingbiel D; Dietrich PY; Hitz F; Bargetzi M; Mingrone W; Martinelli G; Trojan A; Bouabdallah K; Lohri A; Gyan E; Biaggi C; Cogliatti S; Bertoni F; Ghielmini M; Brauchli P; Ketterer N;
    Haematologica; 2012 Jul; 97(7):1085-91. PubMed ID: 22315486
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.
    Dancey JE; Curiel R; Purvis J
    Semin Oncol; 2009 Dec; 36 Suppl 3():S46-58. PubMed ID: 19963100
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Temsirolimus in relapsed and/or refractory mantle cell lymphoma†: profile report.
    Hoy SM; McKeage K
    BioDrugs; 2011 Jun; 25(3):193-5. PubMed ID: 21627343
    [No Abstract]   [Full Text] [Related]  

  • 56. Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany.
    Gerullis H; Bergmann L; Maute L; Eimer C; Otto T
    Cancer Chemother Pharmacol; 2009 May; 63(6):1097-102. PubMed ID: 18818922
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
    Olsen EA; Kim YH; Kuzel TM; Pacheco TR; Foss FM; Parker S; Frankel SR; Chen C; Ricker JL; Arduino JM; Duvic M
    J Clin Oncol; 2007 Jul; 25(21):3109-15. PubMed ID: 17577020
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group.
    Conconi A; Raderer M; Franceschetti S; Devizzi L; Ferreri AJ; Magagnoli M; Arcaini L; Zinzani PL; Martinelli G; Vitolo U; Kiesewetter B; Porro E; Stathis A; Gaidano G; Cavalli F; Zucca E
    Br J Haematol; 2014 Jul; 166(1):69-76. PubMed ID: 24673512
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma.
    Galimberti S; Petrini M
    Cancer Manag Res; 2010 Jun; 2():181-9. PubMed ID: 21188109
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.
    Witzig TE; Luigi Zinzani P; Habermann TM; Tuscano JM; Drach J; Ramchandren R; Kalayoglu Besisik S; Takeshita K; Casadebaig Bravo ML; Zhang L; Fu T; Goy A
    Am J Hematol; 2017 Oct; 92(10):E575-E583. PubMed ID: 28699256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.